FDA Convenes Advisory Committee for the Second Time for ALS Therapy
July 5th 2022The Peripheral and Central Nervous System Drugs Advisory Committee will meet for a second time in September 2022 to discuss new analysis of the data for AMX0035 for the treatment of patients with amyotrophic lateral sclerosis.
Removing Prior Authorization Can Increase Access to Opioid Use Treatments
July 3rd 2022The removal of prior authorizations for buprenorphine for use in opioid use disorder was associated with a statistically significant increase in the number of prescriptions filled among Medicaid populations in Illinois but not in California, which had already been seeing an increase in use of such therapies.